Published in Immunology on June 01, 2006
Dendritic cells and the control of immunity. Nature (1998) 56.54
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol (1999) 9.55
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 4.92
Biology and clinical relevance of human natural killer cells. Blood (1990) 3.50
Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 3.35
CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A (1997) 3.25
Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med (1994) 3.24
Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol (1997) 2.81
Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med (1993) 2.62
CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med (1997) 2.51
The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol (2005) 2.43
Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol (2004) 1.90
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation (1995) 1.63
Targeting of human dendritic cells by autologous NK cells. J Immunol (1999) 1.62
Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 1.51
Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice. Nat Med (2001) 1.49
Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Eur J Immunol (1995) 1.43
Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int Immunol (1994) 1.32
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol (2002) 1.32
A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J (2000) 1.16
NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J Immunol (2004) 1.11
Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood (2005) 1.09
Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation (1997) 1.08
Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation (1998) 1.01
Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther (2001) 0.93
Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer (2002) 0.91
A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival. Transplantation (2000) 0.85
Proteomic analysis of human natural killer cells: insights on new potential NK immune functions. Mol Immunol (2005) 0.82
Further evidence that NK cells may contribute to the development of cardiac allograft vasculopathy. Transplant Proc (2005) 0.78
Ovine dendritic cells transduced with an adenoviral CTLA4eEGFP fusion protein construct induce hyporesponsiveness to allostimulation. Immunology (2004) 0.77
West African Ebola epidemic after one year--slowing but not yet under control. N Engl J Med (2014) 2.96
Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol (2006) 1.73
Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transpl Int (2010) 1.39
Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int (2005) 0.97
Site-specific protein modification to identify the MutL interface of MutH. Nucleic Acids Res (2003) 0.84
Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal vs. long-term cyclosporin therapy in Australia. Clin Transplant (2006) 0.83
Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunol Lett (2008) 0.82
Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int (2007) 0.82
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int (2014) 0.80
IFN-gamma generates maturation-arrested dendritic cells that induce T cell hyporesponsiveness independent of Foxp3+ T-regulatory cell generation. Immunol Lett (2010) 0.80
A review of utility-based allocation strategies to maximize graft years of deceased donor kidneys. Nephrology (Carlton) (2011) 0.80
Effects of topical administration of 12-methyl tetradecanoic acid (12-MTA) on the development of corneal angiogenesis. Angiogenesis (2007) 0.78
Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology (Carlton) (2013) 0.78
Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J Immunol (2005) 0.78
Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation (2009) 0.78
Extrafacial microcystic adnexal carcinoma: case report and review of the literature. Dermatol Surg (2009) 0.78
Ovine dendritic cells transduced with an adenoviral CTLA4eEGFP fusion protein construct induce hyporesponsiveness to allostimulation. Immunology (2004) 0.77
Cloning and expression of the ovine CD40 molecule and the inhibition of the mixed lymphocyte reaction by the ovine CD40(e)-EGFP fusion protein. Vet Immunol Immunopathol (2002) 0.77
Disseminated microsporidiosis with Encephalitozoon species in a renal transplant recipient. Nephrology (Carlton) (2012) 0.77
Geographic variance in access to renal transplantation in Australia. Transplantation (2003) 0.76
A prospective, multinational pharmacoepidemiological study of clinical conversion to sirolimus immunosuppression after renal transplantation. J Transplant (2012) 0.75
A Single Center Experience With Adult Dual Kidney Transplant. Exp Clin Transplant (2015) 0.75